Login to Your Account

Antigenics’ Oncophage Misses In Phase III Renal Cancer Trial

By Randall Osborne

Monday, March 27, 2006
Apparently bad - and somewhat puzzling - early news from the Phase III trial with its personalized kidney cancer vaccine sent Antigenics Inc.’s stock reeling. The company has suspended part two of the study while analyzing top-line data from the first part, and planning more changes at the firm to reduce the burn rate. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription